Genprex, Inc. short interest in 2023
In 2023, Genprex, Inc.'s disclosed short interest ran from 3.43% of shares outstanding on 13 Jan 2023 to 2.31% on 29 Dec 2023, a change of -1.12 percentage points. The year's high was 5.71% on 28 Feb 2023 and its low 1.84% on 15 Dec 2023, averaging 3.48% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.51 days on 14 Apr 2023. Full history: Genprex, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 3.43% (13 Jan 2023)
- End of year
- 2.31% (29 Dec 2023)
- Change
- -1.12 pp
- High
- 5.71% (28 Feb 2023)
- Low
- 1.84% (15 Dec 2023)
- Average
- 3.48%
- Highest days to cover
- 15.51 (14 Apr 2023)
- SEC filings marked
- 4
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 3.43% | 3.41 | |
| 31 Jan 2023 | 3.64% | 12.12 | |
| 15 Feb 2023 | 3.74% | 13.13 | |
| 28 Feb 2023 | 5.71% | 2.00 | |
| 15 Mar 2023 | 3.73% | 5.57 | |
| 31 Mar 2023 | 3.31% | 7.68 | 10-K filed |
| 14 Apr 2023 | 3.18% | 15.51 | |
| 28 Apr 2023 | 4.34% | 1.46 | |
| 15 May 2023 | 3.61% | 12.44 | |
| 31 May 2023 | 3.86% | 6.06 | 10-Q filed |
| 15 Jun 2023 | 3.64% | 5.18 | |
| 30 Jun 2023 | 5.66% | 2.41 | |
| 14 Jul 2023 | 4.39% | 6.24 | |
| 31 Jul 2023 | 4.90% | 2.21 | |
| 15 Aug 2023 | 3.55% | 2.34 | |
| 31 Aug 2023 | 2.87% | 3.85 | 10-Q filed |
| 15 Sep 2023 | 2.98% | 10.16 | |
| 29 Sep 2023 | 2.78% | 7.12 | |
| 13 Oct 2023 | 3.04% | 6.48 | |
| 31 Oct 2023 | 2.76% | 3.35 | |
| 15 Nov 2023 | 2.26% | 3.68 | 10-Q filed |
| 30 Nov 2023 | 1.98% | 7.49 | |
| 15 Dec 2023 | 1.84% | 3.30 | |
| 29 Dec 2023 | 2.31% | 3.01 |
See also: Genprex, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.